home

Genocea Announces Positive Durability Data from 6-Month Analysis of Phase 2 Clinical Trial of Genital Herpes Immunotherapy GEN-003

R&DPharmacodia.com2015-10-08 00:00 Read   180

Genocea Biosciences, Inc., a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. At its best performing dose of 60 µg per protein / 75 µg of Matrix-M2TM adjuvant, GEN-003 demonstrated a statistically significant 58 percent reduction from baseline in the viral shedding rate (p<0.0001), the primary endpoint of the study.

Seattle Genetics Announces Initiation of Phase 1/2 Clinical Trial of ADCETRIS® (Brentuximab Vedotin) in Combination with Opdivo® (Nivolumab) in Second-line Hodgkin Lymphoma

R&DPharmacodia.com2015-10-08 00:00 Read   230

Seattle Genetics, Inc.today announced that it has initiated a phase 1/2 clinical trial of ADCETRIS (brentuximab vedotin) in combination with Opdivo (nivolumab) for patients with relapsed or refractory Hodgkin lymphoma (HL) after failure of frontline treatment.

Pivotal Phase 3 Studies of Bezlotoxumab, Merck’s Investigational Antitoxin to Prevent Clostridium Difficile Infection Recurrence, Met Primary Endpoint

R&DPharmacodia.com2015-09-22 00:00 Read   946

Merck, known as MSD outside the United States and Canada, today announced that the two pivotal Phase 3 clinical studies for bezlotoxumab, its investigational antitoxin for prevention of Clostridium difficile (C. difficile) infection recurrence, met their primary efficacy endpoint: the reduction in C. difficile recurrence through week 12 compared to placebo, when used in conjunction with standard of care antibiotics for the treatment of C. difficile. Based on these results, the company plans to submit new drug applications seeking regulatory approval of bezlotoxumab in the U.S., EU and Canada in 2015. Currently, there are no therapies approved for the prevention of recurrent disease caused by C. difficile.

Arno’s AR-12: first-in-class, novel mechanism, broad-spectrum antimicrobial drug

R&DPharmacodia.com2015-09-21 00:00 Read   427

Arno Therapeutics, Inc., a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for cancer and other life threatening diseases, today announced promising data demonstrating novel activity of AR-12 as a broad-spectrum, anti-microbial drug.

Johnson & Johnson And Achillion Pharmaceuticals May Offer Fastest 100% Cure With Their HCV Combo

R&DPharmacodia.com2015-09-20 00:00 Read   319

Achillion Pharmaceuticals, Inc. reported on Thursday additional interim results from a mid-stage study evaluating safety and efficacy of its experimental hepatitis C drug, ACH-3102 (odalasvir), within six to eight weeks of treatment. The positive results might help to reinstate investor interest in the biotech company’s stock, after the year-to-date slump. Achillion stock traded up 7.38% on the news to close at $8.58 on Thursday.

Adding iridium may offer a new approach to antibiotic resistance

R&DPharmacodia.com2015-09-19 00:00 Read   241

Virginia Tech researchers say that they have developed a new antibiotic that includes iridium, a "transition metal" that keeps them from breaking down and improving delivery to fight infections.

Zealand advances its proprietary, long-acting GLP-2 analogue, ZP1848, into clinical Phase II development for the treatment of Short Bowel Syndrome

R&DPharmacodia.com2015-09-17 00:00 Read   860

Zealand announces the initiation of a clinical Phase II development program for its proprietary peptide therapeutic, ZP1848, for the treatment of Short Bowel Syndrome (SBS). ZP1848 is a long-acting, stable and soluble GLP-2 receptor agonist invented and wholly owned by Zealand.

New data demonstrates Jardiance (empagliflozin) showed a significant reduction in cardiovascular risk in diabetes patients in a dedicated outcome trial

R&DPharmacodia.com2015-09-17 00:00 Read   658

Patients with type 2 diabetes at high risk for cardiovascular events who received empagliflozin, as compared with placebo, had a lower rate of the primary composite cardiovascular outcome and of death from any cause when the study drug was added to standard care.

Advaxis gets a whiplash after its upbeat assessment of PhII cancer vaccine data

R&DPharmacodia.com2015-09-17 00:00 Read   338

Advaxis says that a small study for cervical cancer produced promising outcomes for a significant number of the 26 patients involved.That assessment was initially spurned by the market, with the stock plunging close to 30% before immediately bouncing back and hovering around even Thursday afternoon.

Gene therapy player Dimension catches the biotech IPO wave, files $115M offering

R&DPharmacodia.com2015-09-14 00:00 Read   277

Dimension Therapeutics is preparing to execute the next carefully planned step in its evolution, filing for a $115 million IPO close to 5 months after its crossover round landed.